针对血液性恶性瘤进行第三次造血细胞移植的患者的结果
Emily R Cox1, Corinne Summers1,2, Filippo Milano1,3
1Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.
Annals of hematology
|July 13, 2024
概括
第三次造血细胞移植 (HCT3) 为复发性血液性恶性瘤提供了一个治疗选择. 然而,HCT3后的长期存活率仍然很差,这凸显了需要改进治疗策略的需要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 移植医学 移植医学
背景情况:
- 新型治疗方法的进步挑战了第三个造血细胞移植 (HCT3) 对于复发性血液性恶性瘤的既定作用.
- 在不断变化的治疗环境中,HCT3的疗效和结果需要仔细评估.
研究的目的:
- 评估HCT3在2000年至2020年期间接受该程序的血液恶性瘤患者的可行性和结果.
- 确定在高度精选的患者队列中,在HCT3后的生存率和死亡原因.
主要方法:
- 对接受HCT3.3的9名患有血液性恶性瘤的患者进行了回顾性分析.
- 评估患者人口统计学,疾病类型,移植之间的时间间隔,HCT3的指示,缓解状态,移植和生存结果.
主要成果:
- 这项研究包括患有急性骨髓性白血病,急性淋巴细胞白血病,骨髓失质综合征和不分化急性白血病的患者.
- 9名患者中有8人死于复发,非复发原因或未知原因,中位数在HCT3.3后0.6年内死亡.
- 在HCT3后6个月,1年和5年的估计整体生存率分别为88%,63%和22%.
结论:
- 在第二次HCT后,HCT3可以作为高度选择的患有复发或移植失败的血液恶性瘤患者的治疗选择.
- 尽管最初的移植成功,但HCT3后的长期存活率仍然令人丧,这强调了需要进一步研究和改进的治疗方法.
相关概念视频
01:22Bone Marrow Sampling and Transplants
323
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
323
01:24Tissue Transplantation
354
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
354
01:21Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
01:01Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
01:19Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K